Abbott price target lowered to $136 from $140 at Citi
Citi analyst Joanne Wuensch lowered the firm’s price target on Abbott (ABT) to $136 from $140 and keeps a Buy rating on the shares. The firm adjusted targets in the medical technology group post the Q4 reports. Sector fundamentals remain “healthy” despite the recent volatility, the analyst tells investors in a research note. Citi’s top picks are iRhythm and Medtronic.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Read More on ABT:
Disclaimer & DisclosureReport an Issue
- Abbott Laboratories Completes Major Senior Notes Offering
- Mercadolibre, Dell, Lam, QuantumScape, Abbott: Insider Shake-Up
- FDA approves Abbott CardioMEMS Hero device for people living with heart failure
- Abbott Laboratories Prices $20 Billion Senior Notes Offering
- 3 Best Dividend Aristocrat Stocks to Buy Now, 02/26/2026
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
XRP Rich List Barrier Falls As Wallets Hit This Milestone
Veteran Macro Investor Says AI’s Easy Money Is Over and Bitcoin Is Next
RLUSD Gets Two Major Institutional Boosts as Monthly Volume Drops 25%: What It Could Mean for XRP Holders
The Next Meme Coin Winner Could Be Determined by Incentives, Not Memes
Crypto prices
More
